Genes & DiseasesPub Date : 2024-06-26DOI: 10.1016/j.gendis.2024.101325
Yutong Wang , Yulan Yao , Sen Kou , Shanshan Wang , Juntao Song , Siqi Yang , Hongwei Wang , Yunliang Wang
{"title":"SIK2 promotes malignant features of human osteosarcoma via up-regulating MMP2 and β-catenin expression","authors":"Yutong Wang , Yulan Yao , Sen Kou , Shanshan Wang , Juntao Song , Siqi Yang , Hongwei Wang , Yunliang Wang","doi":"10.1016/j.gendis.2024.101325","DOIUrl":"10.1016/j.gendis.2024.101325","url":null,"abstract":"","PeriodicalId":12689,"journal":{"name":"Genes & Diseases","volume":"12 2","pages":"Article 101325"},"PeriodicalIF":6.9,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141547900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Genes & DiseasesPub Date : 2024-06-25DOI: 10.1016/j.gendis.2024.101367
Run Yang , Xin Chen , Siyi Wu , Chenlong Li , Ying Chen , Yaoyao Fu , Aijuan He , Duan Ma , Jing Ma , Tianyu Zhang
{"title":"HOXB6 down-regulation induced by retinoic acid pathway repression leads to chondrocyte proliferation inhibition and apoptosis in microtia","authors":"Run Yang , Xin Chen , Siyi Wu , Chenlong Li , Ying Chen , Yaoyao Fu , Aijuan He , Duan Ma , Jing Ma , Tianyu Zhang","doi":"10.1016/j.gendis.2024.101367","DOIUrl":"10.1016/j.gendis.2024.101367","url":null,"abstract":"","PeriodicalId":12689,"journal":{"name":"Genes & Diseases","volume":"12 3","pages":"Article 101367"},"PeriodicalIF":6.9,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141547895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Genes & DiseasesPub Date : 2024-06-22DOI: 10.1016/j.gendis.2024.101355
Xiaoya Zhang, Guiqiu Xie, Lang Rao, Chaoguang Tian
{"title":"Protein citrullination in gene transcription regulation and physiological implications","authors":"Xiaoya Zhang, Guiqiu Xie, Lang Rao, Chaoguang Tian","doi":"10.1016/j.gendis.2024.101355","DOIUrl":"https://doi.org/10.1016/j.gendis.2024.101355","url":null,"abstract":"Protein citrullination involves the deimination of arginine or methylarginine residues in peptide chains to form citrulline by peptidyl arginine deiminases. This process is an important protein post-translational modification that affects molecular structure and function of various proteins, including histones. In recent years, protein citrullination has attracted widespread attention for its influence on gene transcription. Studies on the impact of protein citrullination modification on chromatin structure remodeling and the establishment of gene regulatory networks have made rapid progress. In this review, we briefly summarize the physiological functions of protein citrullination modification. Specifically, we comprehensively outline the latest progress in the study of the role of protein citrullination modification in gene transcription regulation, focusing on the interaction of protein citrullination with other post-translational modifications.","PeriodicalId":12689,"journal":{"name":"Genes & Diseases","volume":"24 1","pages":""},"PeriodicalIF":6.8,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141547897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Genes & DiseasesPub Date : 2024-06-21DOI: 10.1016/j.gendis.2024.101358
Qing Pan , Wenbo Yang , Fuhua Huang , Wei Wu, Zengwu Shao, Zhicai Zhang
{"title":"EWSR1-PSMC5 fusion gene variously activating autophagy in drug resistance of osteosarcoma: A novel gene fusion model report and mechanism research","authors":"Qing Pan , Wenbo Yang , Fuhua Huang , Wei Wu, Zengwu Shao, Zhicai Zhang","doi":"10.1016/j.gendis.2024.101358","DOIUrl":"10.1016/j.gendis.2024.101358","url":null,"abstract":"","PeriodicalId":12689,"journal":{"name":"Genes & Diseases","volume":"12 3","pages":"Article 101358"},"PeriodicalIF":6.9,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141547896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Genes & DiseasesPub Date : 2024-06-20DOI: 10.1016/j.gendis.2024.101356
Yang Wang , Naijipu Abuduaini , Wenjuan Liu , Yuanjun Song , Zunping Ke , Xilong Wang , Wei Jiao , Si Chen , Xianhua Lin , Weiwei Yu , Weiqiang Lu , Bo Feng , Jiacheng He
{"title":"Shikonin is a novel antagonist of prostaglandin E2 receptor 4 that targets myeloid-derived suppressor cells","authors":"Yang Wang , Naijipu Abuduaini , Wenjuan Liu , Yuanjun Song , Zunping Ke , Xilong Wang , Wei Jiao , Si Chen , Xianhua Lin , Weiwei Yu , Weiqiang Lu , Bo Feng , Jiacheng He","doi":"10.1016/j.gendis.2024.101356","DOIUrl":"10.1016/j.gendis.2024.101356","url":null,"abstract":"","PeriodicalId":12689,"journal":{"name":"Genes & Diseases","volume":"12 3","pages":"Article 101356"},"PeriodicalIF":6.9,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141547898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Genes & DiseasesPub Date : 2024-06-17DOI: 10.1016/j.gendis.2024.101353
Muyuan Ma, Jianhong An, Tingting Jiang, Keping Xie
{"title":"GATA6 in pancreatic cancer initiation and progression","authors":"Muyuan Ma, Jianhong An, Tingting Jiang, Keping Xie","doi":"10.1016/j.gendis.2024.101353","DOIUrl":"10.1016/j.gendis.2024.101353","url":null,"abstract":"<div><div>Pancreatic ductal adenocarcinoma (PDA) is a lethal malignancy characterized by insidious onset and lack of effective therapy. The molecular pathogenesis of PDA remains to be understood fully. Transcriptional factor GATA6 is an important transcriptional regulator in normal pancreas development, particularly in the initial specification and differentiation of the pancreas. Recent studies have linked pancreatic malignancy closely to GATA6. Increased levels of GATA6 expression enhance pancreatic cancer cell growth. GATA6 emerges as a lineage-specific oncogenic factor in PDA, augmenting the oncogenic phenotypes of PDA cells upon its overexpression. However, elevated GATA6 levels are correlated with well-differentiated tumors and a more favorable patient prognosis. Experimental evidence in genetic mouse models has revealed a tumor-suppressive role for GATA6. The circumstantial roles of GATA6 in pancreatic tumorigenesis remain to be defined. This review aims to elucidate recent advances in comprehending GATA6, emphasizing its crucial roles in both pancreas physiology and pathology. Special attention will be given to its involvement in PDA pathogenesis, exploring its potential as a novel biomarker and a promising therapeutic target for PDA.</div></div>","PeriodicalId":12689,"journal":{"name":"Genes & Diseases","volume":"12 2","pages":"Article 101353"},"PeriodicalIF":6.9,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141547899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Genes & DiseasesPub Date : 2024-06-17DOI: 10.1016/j.gendis.2024.101354
Omkar Desai, Moeez Rathore, Christina S. Boutros, Michel'le Wright, Elizabeth Bryson, Kimberly Curry, Rui Wang
{"title":"HER3: Unmasking a twist in the tale of a previously unsuccessful therapeutic pursuit targeting a key cancer survival pathway","authors":"Omkar Desai, Moeez Rathore, Christina S. Boutros, Michel'le Wright, Elizabeth Bryson, Kimberly Curry, Rui Wang","doi":"10.1016/j.gendis.2024.101354","DOIUrl":"https://doi.org/10.1016/j.gendis.2024.101354","url":null,"abstract":"HER3, formally referred to as ERB-B2 receptor tyrosine kinase 3, is a member of the ErbB receptor tyrosine kinases (also known as EGFR) family. HER3 plays a significant pro-cancer role in various types of cancer due to its overexpression and abnormal activation, which initiates downstream signaling pathways crucial in cancer cell survival and progression. As a result, numerous monoclonal antibodies have been developed to block HER3 activation and subsequent signaling pathways. While pre-clinical investigations have effectively showcased significant anti-cancer effects of HER3-targeted therapies, these therapies have had little impact on cancer patient outcomes in the clinic, except for patients with rare fusion mutations. This review offers a comprehensive description of the oncogenic functions of HER3, encompassing its structure and mediating signaling pathways. More importantly, it provides an in-depth exploration of past and ongoing clinical trials investigating HER3-targeted therapies for distinct types of cancer and discusses the tumor microenvironment and other critical determinants that may contribute to the observed suboptimal outcomes in most clinical studies using HER3-targeted therapies. Lastly, we suggest alternative approaches and the exploration of novel strategies to potentially improve the efficacy of targeting the pivotal oncogenic HER3 signaling pathway in future translational investigations.","PeriodicalId":12689,"journal":{"name":"Genes & Diseases","volume":"40 1","pages":""},"PeriodicalIF":6.8,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141547916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}